NCT01568411View on ClinicalTrials.gov

A Fixed-Sequence, Two-Period, Open-Label Drug-Drug Interaction Study to Assess the Effect of an Inhibitor of Cytochrome P450 Isoenzyme 3A4 and Permeability Glycoprotein 1 on the Pharmacokinetics of TD-1211

PHASE1CompletedINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

April 30, 2012

Primary Completion Date

June 30, 2012

Study Completion Date

June 30, 2012

Conditions
Healthy
Interventions
DRUG

TD-1211

Period 1

DRUG

TD-1211+ itraconazole

Period 2

Trial Locations (1)

78209

Icon Development Services, San Antonio

Sponsors
All Listed Sponsors
lead

Theravance Biopharma

INDUSTRY

NCT01568411 - A Fixed-Sequence, Two-Period, Open-Label Drug-Drug Interaction Study to Assess the Effect of an Inhibitor of Cytochrome P450 Isoenzyme 3A4 and Permeability Glycoprotein 1 on the Pharmacokinetics of TD-1211 | Biotech Hunter | Biotech Hunter